ストックスクリーナーアプリを入手
253.42
0.17%
-0.44
アフターアワーズ：
253.34
-0.08
-0.03%
Ascendis Pharma A S (ASND) 最新ニュース
ASND|Ascendis Pharma A/S|Price:256.235|Chg%:+2.375 - TradingKey
Ascendis Pharma A/S (ASND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ascendis Pharma A/S (ASND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns - Yahoo Finance
Ascendis Pharma AS (STU:A710) Shiller PE Ratio : (As of Jul. 24, 2026) - GuruFocus
ASND|Ascendis Pharma A/S|Price:253.204|Chg%:-0.656 - TradingKey
Goldman Sachs Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $300 - 富途牛牛
Ascendis Pharma (ASND) Could Be 14% Below Fair Value As Growth Hopes Hold - simplywall.st
Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup - ChartMill
Ascendis Pharma A/S (ASND) Stock Analysis: Unpacking a 15.68% Potential Upside for Investors - DirectorsTalk Interviews
Tranche Update on Ascendis Pharma A/S's Equity Buyback Plan announced on February 12, 2025. - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
(ASND) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ASND5566766 Bond Profile — Key Metrics - TradingView
Price to earnings forward of Ascendis Pharma A/S – DUS:A710 - TradingView
Ascendis Pharma (ASND) grants 14,060 employee warrants at $265.57 - Stock Titan
Price to book forward of Ascendis Pharma A/S – DUS:A710 - TradingView
Enterprise value to EBITDA forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
BofA raises Ascendis Pharma stock price target on revenue outlook By Investing.com - Investing.com India
Enterprise value to EBITDA forward of Ascendis Pharma A/S – DUS:A710 - TradingView
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $306 - Moomoo
BofA raises Ascendis Pharma stock price target on revenue outlook - Investing.com
Ascendis Pharma: Precision in Princeton - New Jersey Business Magazine
Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Giant with 144% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
Price to sales forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Enterprise value to EBIT forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia - Yahoo Finance
Enterprise value to revenue forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong - simplywall.st
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24% - Yahoo Finance
Price to earnings forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Enterprise value to revenue forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Enterprise value to EBITDA forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Ascendis Pharma : ASND - 24/7 Wall St.
Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says - Moomoo
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $327 - Moomoo
Ascendis Pharma (ASND) Investor Update Summary - Quartr
Ascendis Pharma (ASND) Q3 2025 earnings summary - Quartr
Ascendis Pharma (ASND) Q3 2024 earnings summary - Quartr
Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $345 - Moomoo
Ascendis Pharma (ASND) Study Update Summary - Quartr
RBC Capital Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $280 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
RBC Capital Adjusts Ascendis Pharma Price Target to $280 From $275, Maintains Outperform Rating - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Analysis: Strong Buy Ratings and Promising Revenue Growth Capture Investor Interest - DirectorsTalk Interviews
ASNDAscendis Pharma A/S Volatility & Greeks - Finviz
Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data - simplywall.st
Ascendis Pharma Q2 2025 Earnings Preview - MSN
Ascendis Pharma: Behind The Stock Surge - Seeking Alpha
Ascendis Pharma added to Russell 3000, Russell 1000 and other US indexes - MSN
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia - TipRanks
Ascendis Pharma (ASND) shares 2-year TransCon CNP ApproaCH achondroplasia results - Stock Titan
Ascendis Pharma A/S Announces New Radiographic Data from Week 104 of the Completed Pivotal Approach Trial of Once-Weekly Transcon Cnp in Children with Achondroplasia - marketscreener.com
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial - TipRanks
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):